130 related articles for article (PubMed ID: 29239826)
1. Circulating cathelicidin LL-37 level is increased in euthymic patients with bipolar disorder.
Kozłowska E; Żelechowska P; Brzezińska-Błaszczyk E; Margulska A; Wysokiński A
J Clin Neurosci; 2018 Feb; 48():168-172. PubMed ID: 29239826
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of peptide cathelicidin LL-37 in elderly patients with depression.
Kozłowska E; Wysokiński A; Brzezińska-Błaszczyk E
Psychiatry Res; 2017 Sep; 255():156-160. PubMed ID: 28550757
[TBL] [Abstract][Full Text] [Related]
3. Human cathelicidin LL-37 - Does it influence the homeostatic imbalance in mental disorders?
Kozlowska E; Wysokinski A; Majewski K; Agier J; Margulska A; Brzezinska-Blaszczyk E
J Biosci; 2018 Jun; 43(2):321-327. PubMed ID: 29872020
[TBL] [Abstract][Full Text] [Related]
4. Body composition does not affect serum levels of cathelicidin LL-37 in elderly women with unipolar depression.
Szczepocka E; Kozłowska E; Brzezińska-Błaszczyk E; Wysokiński A
Nord J Psychiatry; 2018 Jan; 72(1):45-50. PubMed ID: 28959904
[TBL] [Abstract][Full Text] [Related]
5. Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases.
Majewski K; Żelechowska P; Brzezińska-Błaszczyk E
Clin Invest Med; 2017 Feb; 40(1):E34-E39. PubMed ID: 28218580
[TBL] [Abstract][Full Text] [Related]
6. Circulating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn's disease, and clinical prognosis in inflammatory bowel disease.
Tran DH; Wang J; Ha C; Ho W; Mattai SA; Oikonomopoulos A; Weiss G; Lacey P; Cheng M; Shieh C; Mussatto CC; Ho S; Hommes D; Koon HW
BMC Gastroenterol; 2017 May; 17(1):63. PubMed ID: 28494754
[TBL] [Abstract][Full Text] [Related]
7. Serum level of cathelicidin LL-37 in patients with active tuberculosis and other infectious diseases.
Majewski K; Agier J; Kozłowska E; Brzezińska-Błaszczyk E
J Biol Regul Homeost Agents; 2017; 31(3):731-736. PubMed ID: 28956425
[TBL] [Abstract][Full Text] [Related]
8. Gingival crevicular fluid levels of cathelicidin LL-37 and interleukin-18 in patients with chronic periodontitis.
Türkoğlu O; Emingil G; Kütükçüler N; Atilla G
J Periodontol; 2009 Jun; 80(6):969-76. PubMed ID: 19485828
[TBL] [Abstract][Full Text] [Related]
9. Status of cathelicidin IL-37, cytokine TNF, and vitamin D in patients with pulmonary tuberculosis.
Majewski K; Agier J; Kozłowska E; Brzezińska-Błaszczyk E
J Biol Regul Homeost Agents; 2018; 32(2):321-325. PubMed ID: 29685013
[TBL] [Abstract][Full Text] [Related]
10. Effect of narrowband ultraviolet B therapy on serum vitamin D and cathelicidin (LL-37) in patients with chronic plaque psoriasis.
Al-Mutairi N; Shaaban D
J Cutan Med Surg; 2014; 18(1):43-8. PubMed ID: 24377473
[TBL] [Abstract][Full Text] [Related]
11. Cathelicidin LL-37 bloodstream surveillance is down regulated during septic shock.
Barbeiro DF; Barbeiro HV; Zampieri FG; César Machado MC; Torggler Filho F; Gomes Cunha DM; Goulart AC; Velasco IT; Monteiro da Cruz Neto L; Possolo de Souza H; Pinheiro da Silva F
Microbes Infect; 2013 May; 15(5):342-6. PubMed ID: 23328115
[TBL] [Abstract][Full Text] [Related]
12. Cathelicidin (LL-37) and its correlation with pro-oxidant, antioxidant balance and disease activity in systemic lupus erythematosus: a cross-sectional human study.
Sahebari M; Roshandel G; Saadati N; Saghafi M; Abdolahi N; Rezaieyazdi Z
Lupus; 2017 Aug; 26(9):975-982. PubMed ID: 28420069
[TBL] [Abstract][Full Text] [Related]
13. Low serum levels of cathelicidin LL-37 in leprosy.
Matzner M; Al Samie AR; Winkler HM; Nemeth J; Grasnek A; Indra A; Bieglmayer C; Winkler S
Acta Trop; 2011 Jan; 117(1):56-9. PubMed ID: 20887706
[TBL] [Abstract][Full Text] [Related]
14. The impact of cathelicidin, the human antimicrobial peptide LL-37 in urinary tract infections.
Babikir IH; Abugroun EA; Bilal NE; Alghasham AA; Abdalla EE; Adam I
BMC Infect Dis; 2018 Jan; 18(1):17. PubMed ID: 29310594
[TBL] [Abstract][Full Text] [Related]
15. Decrease of LL-37 in systemic sclerosis: a new marker for interstitial lung disease?
Hizal M; Bruni C; Romano E; Mazzotta C; Guiducci S; Bellando Randone S; Blagojevic J; Lepri G; Tufan A; Matucci Cerinic M
Clin Rheumatol; 2015 Apr; 34(4):795-8. PubMed ID: 25597616
[TBL] [Abstract][Full Text] [Related]
16. Unique features of human cathelicidin LL-37.
Bandurska K; Berdowska A; Barczyńska-Felusiak R; Krupa P
Biofactors; 2015; 41(5):289-300. PubMed ID: 26434733
[TBL] [Abstract][Full Text] [Related]
17. Circulating LL-37 is a biomarker for eczema severity in children.
Leung TF; Ching KW; Kong AP; Wong GW; Chan JC; Hon KL
J Eur Acad Dermatol Venereol; 2012 Apr; 26(4):518-22. PubMed ID: 21518024
[TBL] [Abstract][Full Text] [Related]
18. Cathelicidin (LL-37) level in the scalp hair of patients with tinea capitis.
Abdelaal NH; Rashed LA; Ibrahim SY; Abd El Halim MH; Ghoneim N; Saleh NA; Saleh MA
Med Mycol; 2017 Oct; 55(7):733-736. PubMed ID: 27915299
[TBL] [Abstract][Full Text] [Related]
19. Design of Antimicrobial Peptides: Progress Made with Human Cathelicidin LL-37.
Wang G; Narayana JL; Mishra B; Zhang Y; Wang F; Wang C; Zarena D; Lushnikova T; Wang X
Adv Exp Med Biol; 2019; 1117():215-240. PubMed ID: 30980360
[TBL] [Abstract][Full Text] [Related]
20. LL-37 but Not 25-Hydroxy-Vitamin D Serum Level Correlates with Healing of Venous Leg Ulcers.
Krejner A; Litwiniuk M; Grzela T
Arch Immunol Ther Exp (Warsz); 2017 Oct; 65(5):455-461. PubMed ID: 27663530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
